Retrospective Cohort Study
Copyright ©The Author(s) 2020.
World J Gastrointest Oncol. Dec 15, 2020; 12(12): 1381-1393
Published online Dec 15, 2020. doi: 10.4251/wjgo.v12.i12.1381
Table 2 Incidence of cholangiocarcinoma among patients with choledocholithiasis who underwent therapeutic endoscopic retrograde cholangiopancreatography, endoscopic retrograde cholangiopancreatography and cholecystectomy, or no intervention compared with normal population (excluding cholangiocarcinoma in the first 18 mo)
Variable
Person-years at risk in study cohort
Person-years at risk in control cohort
No. of observed cases of cholangiocarcinoma in study cohort
No. of observed cases of cholangiocarcinoma in control cohort
Incidence rate/1000 person-years (95%CI) in study cohort
Incidence rate/1000 person-years (95%CI) in control cohort
P value
ES/EPBD
Total1659.7025360.071277.23 (3.92-12.29)0.28 (0.12-0.55)< 0.001
Gender
Male889.9513822.88434.50 (1.43-10.84)0.22 (0.06-0.59)< 0.001
Female769.7611537.208410.39 (4.83-19.74)0.35 (0.11-0.84)< 0.001
Age, years
18-49253.844392.03103.94 (0.20-19.43)0.00 (0.00-0.00)< 0.001
50-69574.788631.76456.96 (2.21-16.79)0.58 (0.21-1.28)< 0.001
> 70831.0812336.28728.42 (3.68-16.66)0.16 (0.03-0.54)< 0.001
ES/EPBD and CCY
Total393.1125360.07172.54 (0.13-12.55)0.28 (0.12-0.55)0.011
Gender
Male184.3613822.88030.00 (0.00-0.00)0.22 (0.06-0.59)0.842
Female208.7511537.20144.79 (0.24-23.63)0.35 (0.11-0.84)0.002
Age, yr
18-49113.014392.03000.00 (0.00-0.00)0.00 (0.00-0.00)NA
50-69143.378631.76156.98 (0.35-34.40)0.58 (0.21-1.28)0.004
> 70136.7312336.28020.00 (0.00-0.00)0.16 (0.03-0.54)0.882
Without intervention
Total4364.4525360.071172.52 (1.35-4.38)0.28 (0.12-0.55)< 0.001
Gender
Male2345.2213822.88632.56 (1.04-5.32)0.22 (0.06-0.59)< 0.001
Female2019.2311537.20542.48 (0.91-5.49)0.35 (0.11-0.84)< 0.001
Age, yr
18-49871.874392.03000.00 (0.00-0.00)0.00 (0.00-0.00)NA
50-691528.748631.76653.93 (1.601-8.16)0.58 (0.21-1.28)< 0.001
> 701963.8412336.28522.55 (0.93-5.64)0.16 (0.03-0.54)< 0.001